Myovant Sciences Ltd.

MYOVDelisted Mar 10, 2023

Industry: Pharmaceutical Preparations
SEC CIK: 0001679082

SEC filings (opens in a new tab)

Myovant Sciences Ltd. was delisted on Mar 10, 2023; its insiders filed their last Form 4 on Mar 10, 2023; 118 institutions reported holding it in 13F filings for Q4 2022, worth $1.12B in total; no superinvestor held it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 118; Q4 2022, +24 vs. previous quarter
13F value: $1.12B; Reported value at the end of Q4 2022
Superinvestors holding: 0; At the end of Q4 2022

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2022: $231.0M; +289.4% year over year
Net income, FY2022: -$206.0M; No comparable prior period
Free cash flow, FY2022: -$269.5M; −173.1% year over year
Revenue, Q3 FY2023: $100.2M; +84.1% year over year

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2022: $206.0M (89.2% of revenue).

Superinvestors holding MYOV, Q4 2022

Go to the superinvestors tab

No superinvestor reported holding MYOV at the end of Q4 2022.

Latest insider trades

See all insider trades

Open-market purchases and sales by Myovant Sciences Ltd. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change
Mar 10, 2023 (view filing)9:17 AM ET	Mar 10	Same day	Sumitomo Pharma Co., Ltd. and 2 others10% Owner	PPurchase	+51.6M	$27.00	+$1.39B	New position45.8M after
Jan 20, 2023 (view filing)	Jan 18	2 days	Lang MatthewGeneral Counsel & Corp. Secy.	SSale	−1.27K	$26.89	−$34.2K	−0.4%354.3K after
Jan 20, 2023 (view filing)	Jan 18	2 days	Merendino LaurenChief Commercial Officer	SSale	−2.01K	$26.89	−$54.0K	−1.2%169.5K after
Jan 20, 2023 (view filing)	Jan 18	2 days	Marek David CPrincipal Executive Officer	SSale	−8.04K	$26.89	−$216.1K	−1.9%417.6K after
Jan 20, 2023 (view filing)	Jan 18	2 days	Arjona Ferreira Juan CamiloChief Medical Officer	SSale	−1.11K	$26.89	−$29.8K	−0.4%246.7K after
Jan 5, 2023 (view filing)	Jan 4	1 day	Arjona Ferreira Juan CamiloChief Medical Officer	SSale	−2.25K	$26.90	−$60.6K	−0.9%247.8K after
Jan 5, 2023 (view filing)	Jan 4	1 day	Lang MatthewGeneral Counsel & Corp. Secy.	SSale	−2.78K	$26.90	−$74.8K	−0.8%355.6K after
Dec 20, 2022 (view filing)	Dec 16	4 days	Mehra UneekPrincipal Financial Officer	SSale	−2.24K	$26.75	−$59.9K	−1.1%202.7K after
Oct 20, 2022 (view filing)	Oct 18	2 days	Merendino LaurenChief Commercial Officer	SSale	−1.70K	$25.20	−$42.9K	−1.0%171.5K after
Oct 20, 2022 (view filing)	Oct 18	2 days	Marek David CPrincipal Executive Officer	SSale	−11.2K	$25.20	−$281.1K	−2.6%425.6K after

Top 10 13F holders, Q4 2022

See all 118 holders

The largest institutional positions in Myovant Sciences Ltd. at the end of Q4 2022; share changes are against Q3 2022.

Institutions holding MYOV in Q4 2022
Institution	Shares	Value	% of portfolio	Change in shares	Action
FIL Ltd	8,624,543	$232.5M	0.28%	+8,624,543	New
Bellevue Group AG	5,910,639	$159.4M	2.11%	−2,0000.0%	Reduced
State Street Corp	2,910,023	$78.5M	0.00%	+893,665+44.3%	Added
Goldman Sachs Group Inc	2,420,659	$65.3M	0.02%	+1,929,497+392.8%	Added
Carlson Capital L P	1,805,249	$48.7M	3.73%	+1,805,249	New
CNH Partners LLC	1,387,550	$37.4M	0.96%	+1,387,550	New
Highland Capital Management Fund Advisors, L.P.	1,338,030	$36.1M	2.81%	+1,338,030	New
Alpine Associates Management Inc.	1,307,785	$35.3M	1.61%	+1,307,785	New
BlackRock Inc.	1,182,942	$31.9M	0.00%	−3,588−0.3%	Reduced
Janus Henderson Group PLC	1,177,158	$31.7M	0.02%	−2,776,683−70.2%	Reduced